OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 16:26 UTC. Every row links to its source record.

CDH1 cadherin 1

ENSG00000039068 · protein coding · Open Targets profile

Cadherins are calcium-dependent cell adhesion proteins (PubMed:11976333). They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells (PubMed:11976333). Promotes organization of radial actin fiber structure and cellular response to contractile forces, via its interaction with AMOTL2 which facilitates anchoring of radial actin fibers to CDH1 junction complexes at the cell membrane (By similarity). Plays a role in the early stages of desmosome cell-cell junction formation via facilitating the recruitment of DSG2 and DSP to desmosome plaques (PubMed:29999492). Has a potent invasive suppressor role. It is a ligand for integrin alpha-E/beta-7. {ECO:0000250|UniProtKB:F1PAA9, ECO:0000269|PubMed:11976333, ECO:0000269|PubMed:16417575, ECO:0000269|PubMed:29999492}.

In 13 of 15 cancers, the evidence for CDH1 comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751CDH1-related diffuse gastric and lobula…CDH1-related diffuse gastric and lobular breast cancer syndromeCDH1-related diffuse gastric and lobular breast cancer syndrome: germline 0.94Familial gastric cancerFamilial gastric cancerFamilial gastric cancer: germline 0.61ovarian cancerovarian cancerovarian cancer: somatic 0.55ovarian cancer: germline 0.90endometrial carcinomaendometrial carcinomaendometrial carcinoma: somatic 0.64endometrial carcinoma: germline 0.89hereditary breast carcinomahereditary breast carcinomahereditary breast carcinoma: germline 0.93breast adenocarcinomabreast adenocarcinomabreast adenocarcinoma: somatic 0.93ovarian neoplasmovarian neoplasmovarian neoplasm: somatic 0.55ovarian neoplasm: germline 0.86gastric cancergastric cancergastric cancer: germline 0.78gastric adenocarcinomagastric adenocarcinomagastric adenocarcinoma: somatic 0.76gastric adenocarcinoma: germline 0.18hereditary neoplastic syndromehereditary neoplastic syndromehereditary neoplastic syndrome: germline 0.95hereditary diffuse gastric adenocarcino…hereditary diffuse gastric adenocarcinomahereditary diffuse gastric adenocarcinoma: germline 0.95Familial prostate cancerFamilial prostate cancerFamilial prostate cancer: germline 0.87breast cancerbreast cancerbreast cancer: germline 0.86prostate cancerprostate cancerprostate cancer: germline 0.87hereditary breast ovarian cancer syndro…hereditary breast ovarian cancer syndromehereditary breast ovarian cancer syndrome: germline 0.77

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Structure with Ligand
Antibody
UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM, Human Protein Atlas loc
PROTAC
UniProt Ubiquitination, Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.4142700135707855 (upper bound 0.5492500066757202). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of CDH1's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of CDH1's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.